Full Press Release Details
Medical to Share Current Results of a Feasibility
Animal Study Utilizing the LIBERTY Robotic System
to be shared on August 17th during Needham's Virtual Med Tech & Diagnostics Conference
Mass., August 13, 2020 - At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday,
August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using
the Company's LIBERTY Robotic System.
Gadot, CEO, President and Chairman along with other members of the management team are scheduled to conduct one-on-one meetings
during the day. The investor presentation, which will highlight the initial results of the feasibility animal study, will be made
available prior to the first meeting and accessed via the Investors' section, under Presentation + Resources'
of the Company's website at www.microbotmedical.com.
Company's LIBERTY robotic system, which was unveiled in January 2020, is the world first fully disposable robotic system
which features a unique compact design; with the capability to be operated remotely, it is being designed to reduce radiation
exposure as well as the physical strain to the physician. Incorporating the technology the Company acquired from CardioSert into
the LIBERTY Robotic System, it has the potential to eliminate the use of multiple consumables through its "One & Done"
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome
of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical
can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities
and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the
SEC, which are or will be available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by law.